Resistance to doxorubicin (DX) frequently emerges in patients, limiting its use in repeated courses of treatment (Curt et al., 1984; Goldie & Coldman, 1984) . Several authors (for review, see Kaye & Merry, 1985) have demonstrated that one mechanism of resistance to DX involves impaired accumulation and retention of the drug, and that DX-resistant cells are also resistant to compounds having different chemical structures and modes of action. This has been reported in vivo in murine tumours and in vitro in established cell lines from animal and human sources. In cell lines isolated from patients (Shoemaker, 1983; Merry et al., 1986; Louie et al., 1986 ) multi-drug resistance has been reported, whereas reduced drug accumulation has not been observed. Another characteristic of DXresistance, possibly related to reduced drug accumulation, is enhanced production of a membrane glycoprotein with a molecular weight -170,000 daltons. This has been reported in some resistant cell lines (Kartner et al., 1985; Bhalla et al., 1985; Roninson et al., 1984) . Gene amplification is at the origin of this overproduction, as already observed in cells with other resistance mechanisms (Starks & Wahl, 1983) .
We selected a human colon adenocarcinoma cell line (LoVo) isolated from a metastatic nodule for studying DX-resistance; its morphology and biochemical characteristics have been fully described (Drewinko et al., 1976 (Drewinko et al., , 1984 Intracellular drug accumulation Cells were seeded at the concentration of 1.2 x 106 cells/dish (60 mm, 4 ml) and incubated at 37°C for 24 h before treatment; for drug exposure, growth medium was withdrawn and replaced with medium containing 2.5 ugml-1 of DX, daunorubicin (DNR), 4'-deoxy-4'-I-doxorubicin (4'-I-DX) and 4'-deoxy-4'-I-daunorubicin (4'-I-DNR) (Figure 1 (Table I) . LoVo/DX were resistant to DX and DNR (RIs 26.7 and 24.8 respectively) and much less resistant to the iododerivatives 4'-I-DX and 4'-I-DNR (RIs 4.4 and 3 respectively). These cytotoxicity values appear to correlate, at least qualitatively, with the intracellular content of the drugs. Figure 2 shows the net drug content determined on LoVo and LoVo/DX after short exposure. In both cell lines, DX and DNR reached lower intracellular levels than their iododerivatives: Drug content in LoVo/DX was however lower for all four compounds, more markedly for DX and DNR than for 4'-I-DX and 4'-I-DNR. These two iododerivatives have been reported to be active both in vitro and in vivo on P388 murine leukaemia resistant to DX (Geroni et al., 1983; Barbieri et al., 1984) . 4'-I-DX has been further. evaluated and is a clinical candidate since it is much less cardiotoxic than DX and shows good antitumour activity (Arcamone, 1985; Barbieri et al., unpublished) . Cross-resistance studies The cytotoxic activity of different antitumour drugs after 24h exposure to graded concentrations of the compounds is shown in Table II . LoVo/DX cells were resistant to doxorubicin (RI, 30.4) , 25) , vincristine (RI, 22.4) and actinomycin D (RI, 7.8). Lower resistance was observed for aclacinomycin A (RI, 2.87) and mitomycin C (RI, 3.1). No crossresistance was observed with Ara-C; this compound in fact was more active on the resistant line than on the sensitive one. This 'collateral sensitivity' of DXresistant cells to Ara-C has been observed in other studies (Johnson et al., 1978; Bhalla et al., 1985) . A puzzling question is that the low intracellular drug content does not account for the marked differences in sensitivity observed in the resistant line. DX-resistance is probably a multifactorial phenomenon; in fact very recently DX-induced DNA damage was described as being reduced in the P388/DX line (Capranico et al., 1986) even when DX levels were comparable. The impaired drug accumulation is certainly a fundamental effect, since the cross-resistance observed to unrelated antitumour drugs would be difficult to explain by other mechanisms. Besides, we have shown that DX-resistance can be partially overcome with anthracycline analogues able to enter resistant cells. Potentially this represents important therapeutic properties because this new class of anthracyclines might be active on tumours which respond poorly to DX, and could also be used in therapy following DX or DNR treatment.
